Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Menactra Pricing Will Be In Line With Wyeth's Prevnar, Sanofi-Aventis Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Sanofi-Aventis will price its meningococcal conjugate vaccine Menactra in line with Wyeth's pneumococcal vaccine Prevnar

You may also be interested in...



Menactra Launch Slated For March On Heels Of Broad CDC Recommendations

Advisory Committee on Immunization Practices recommends routine meningococcal vaccination for adolescents ages 11-12, those entering high school and college freshmen living in dorms. Panel acknowledges that broad recommendations could lead to supply constraints, Sanofi says.

Menactra Launch Slated For March On Heels Of Broad CDC Recommendations

Advisory Committee on Immunization Practices recommends routine meningococcal vaccination for adolescents ages 11-12, those entering high school and college freshmen living in dorms. Panel acknowledges that broad recommendations could lead to supply constraints, Sanofi says.

Sanofi-Aventis Eyes Expanded Menactra Indication Following Initial Approval

FDA approves the meningococcal conjugate vaccine for patients 11-55 years old; Sanofi-Aventis will submit a sBLA for use in children ages 2-11 by February. The company is currently studying the vaccine in patients under age 2 and will initiate a study evaluating Menactra in subjects over age 55 years by January 2006.

Related Content

Topics

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel